Retatrutide, a new dual stimulator of the GLP-1 target and glucose-dependent released polypeptide (GIP) binding site , is showing promising data in preliminary patient assessments . Ongoing research https://bookmark-template.com/story28507835/retatrutide-emerging-research-and-projected-clinical-applications